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ABSTRACT
Purpose of review: The purpose of this review is to present an overview on
the potential role of gut microbiota as target of intervention against food
allergy.
Recent findings: Many studies suggest a key pathogenetic role for
gut microbiota modifications (dysbiosis) in food allergy development.
Several factors responsible for dysbiosis have been associated with the
occurrence of food allergy, such as caesarean delivery, lack of breast milk,
drugs use (mainly antibiotics and gastric acidity inhibitors), antiseptic agents
use, and low fibers/hight fat diet. No specific bacterial taxa have been
consistently associated with food allergy, but evidence suggests that gut
dysbiosis occurs even before food allergy signs and symptoms presentation.
Data from animal and human studies highlight the ability of particular bacterial
taxa to ferment dietary fibers for the production of short chain fatty acids that
affect host immunity and help to explain their health-promoting role.
Summary: Modulation of gut microbiota composition and/or function
represents a promising strategy for treatment and prevention of food
allergy in childhood.
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INTRODUCTION
D uring the last decades, the pattern of food allergy (FA) ischanged with increased persistence, severity of clinical
manifestations and economic impact (1). Thus, there is a strong
need to develop effective strategies to stimulate oral tolerance
acquisition and maintenance.
The cause of FA is still largely undefined. Based
on current knowledge genetic factors may predispose towards
development of FA among selected individuals; but genetic
variance alone cannot explain the changing pattern of FA,
renewing interest in the role of the environment in shaping
sensitization to food. In particular, many studies suggest a key
pathogenetic role for gut microbiota alterations (dysbiosis) in
FA development.
The purpose of this review is to present an overview on the
potential role of gut microbiota as target of intervention against FA
by providing an answer to four key questions.
Question #1: Is There A Link Between Microbial
Exposure and Food Allergy?
The complex interaction between gut microbiota and
immune and non-immune cells results in an environment that
favours oral tolerance (Fig. 1). The maturation of a healthy gut
microbiota in early life allows for a change in the Th1/Th2 balance,
favoring a Th1 cell response; while dysbiosis alters host-micro-
biota homeostasis producing a shift of the Th1/Th2 cytokine
balance, toward a Th2 response. Colonic microbes induce regu-
latory T cells (Tregs) activation and these cells are depleted in
germ-free mice (2). The microbiota-induced Tregs express the
nuclear hormone receptor RORgt and differentiate along a path-
way that also leads to Th17 cells; while in the absence of RORgt in
the Tregs, there is an expansion of Tregs that express GATA-3 as
well as conventional Th2 cells and Th2-associated pathology is
exacerbated (3). Thus, microbiota educates Tregs to suppress Th2
response, and in the absence of this education process, Tregs can
deviate to a phenotype that not only not suppress FA but contrib-
utes to it (4).
Several factors responsible for dysbiosis have been associ-
ated with the occurrence of FA, such as caesarean delivery, lack of
breast milk, drugs use (mainly antibiotics and gastric acidity
inhibitors), antiseptic agents use, and low fibers/hight fat diet
(2). Data emerging from human studies link the use of antimicrobial
agents to the increasing prevalence of FA. It has been demonstrated
that neonatal antibiotic treatment reduced microbial diversity and
bacterial load in both faecal and ileal samples and enhanced food
allergen sensitization (5). Even low-dose early-life antibiotic
exposure can lead to long-lasting effects on metabolic and immune
responsiveness (6). Maternal use of antibiotics before and during
pregnancy, as well as antibiotic courses during first months of life,
are associated with an increased risk of cow’s milk allergy (CMA)
in infants (7).
A recent study examining the influence of dietary patterns
on the development of FA at the age of two years suggests that
the dietary habits may influence the development of FA by
changing the composition of the gut microbiota. In particular,
an infant diet consisting of high levels of fruits, vegetables, and
home-prepared foods was associated with less FA (8).
Question #2: Is There A Particular Signature in
Food Allergy-Related Dysbiosis?
Although compelling evidence for gut microbiota dysbiosis
association with FA is emerging, some studies have failed to find
differences in infant microbiota according to later allergic status or
have found different changes in gut microbiota. Heterogeneity in
study design, including sampling time points, methods used to
characterize microbiota, and different allergic phenotypes under
study, make it difficult to establish a causal relation between
specific bacterial taxa and development of allergy (2). No specific
bacterial taxa have been consistently associated with FA and a
broad range of microbes isolated from human gut could be involved
in tolerogenic mechanisms. In FA children compare to healthy
subjects, different levels of SCFAs, in particular of butyrate, have
been described (9–11). Thus, it is possible to hypothesize that
different type of dysbiosis could lead to similar effects in term of
SCFAs or of other microbiota-derived metabolites production that
could facilitate the occurrence of FA.
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Question #3: Food Allergy and Changes in Gut
Microbiota Composition: What Comes First?
Recent evidence supports the concept that gut dysbiosis
during early life can influence the subsequent development of
allergic disease (12). In the field of FA, new data suggest that
gut dysbiosis precedes FA. Nakayama et al. profiled the faecal
bacteria compositions in allergic and non-allergic infants and
correlated some changes in gut microbiota composition with allergy
development in later years (13).
Azad et al. found that an increased Enterobacteriaceae/
Bacteroidaceae ratio and low Ruminococcaceae abundance, in
the context of low gut microbiota richness in early infancy, are
associated with subsequent food sensitization, suggesting that early
gut dysbiosis contributes to subsequent development of FA (14).
Question #4: Which are the Good Bugs?
Data from Animal Studies
Regulatory T cells, which express the Foxp3 transcription
factor (Foxp3þTregs), play a critical role in oral tolerance. The
pivotal study from Atarashi et al. showed that the spore-forming
component of gut microbiota, particularly clusters IV and XIVa of
the genus Clostridium, promoted Tregs accumulation in the colonic
mucosa. Colonization of mice by a defined mix of Clostridium
strains provided an environment rich in transforming growth factor
b (TGF-b) and affected colonic Foxp3þ Tregs number and function
(15). In a subsequent study, Atarashi et al. (16) isolated 17 strains
within Clostridia clusters XIVa, IV and XVIII from a human faecal
sample and demonstrated that these strains affect Tregs differen-
tiation, accumulation and function in the mouse colon. Oral inocu-
lation of Clostridium during the early life of conventionally reared
mice resulted in resistance to colitis and systemic immunoglobulin
E responses in adult mice, suggesting a new therapeutic approach to
FA. Clostridia species belonging to cluster IV and XIVa are
the prominent source of SCFAs in the colon. Bacteria-produced
SCFAs have been implicated in the regulation of both the pro-
portions and functional capabilities of colonic Tregs (17), which, in
some studies, has been specifically attributed to butyrate production
by spore-forming Clostridiales (18). Preliminary data from our
laboratory showed that oral butyrate treatment induces a dramatic
inhibition of acute allergic skin response, anaphylactic symptom
score, body temperature decrease, intestinal permeability increase,
anti-bLG lactoglobulin (BLG) IgE, IL-4 and IL-10 production in a
murine model of CMA, suggesting a protective role of butyrate
against FA.
Data from Human Studies
This evidence derived from animal models suggests that
therapeutic modulation of the commensal microbiota may be
beneficial for the prevention and treatment of FA. Studies
FIGURE 1. The oral tolerance network. The oral tolerance network is mainly composed by the well-modulated activity of different components:
gut microbiota (without gut microbiota it is not possible to achieve oral tolerance); food antigens; epithelial cells; dendritic cells; regulatory Tcells.
Food antigens and intestinal microbiota constitute the majority of the antigen load in the intestine. A subset of dendritic cells (DCs) mediates the
selective induction of regulatory T cells (Tregs) in response to food antigens encountered in the gastrointestinal mucosa. CD103þ DCs are
migratory and traffic to the mesenteric lymph nodes (MNL). CD103þ CDs in the MNL express high levels of transforming growth factor (TGF)-b
and the retinoic acid-synthesizing enzyme (RALDH), which facilitate the production of retinoic acid (RA) from vitamin A. CD103þCDs in the MNL
also express the enzyme IDO. TGF-b, RA and IDO are factors that actively promote the development of Tregs from naı¨ve T cells in the MNL. In a
broader view, the complex interaction between intestinal contents and immune and non-immune cells result in an environment that favours the
tolerance by the induction of IgA antibodies and Tregs, which produce IL-10, dispensable for the induction of tolerance to food antigens.
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examining the efficacy of currently available probiotics in
treating FA have yielded conflicting results. Probiotics were
found to lower the risk of eczema when used by women during
the last trimester of pregnancy, by breastfeeding mothers or when
given to infants. Evidence did not support an effect on asthma,
FA, or allergic rhinitis (19). Recently published guidelines for
atopic diseases prevention from the World Allergy Organization
concluded that there is a likely net benefit in using probiotics
in the prevention of eczema in high risk children with a
family history of allergic disease (20). Studies investigating
the therapeutic effect of probiotics on challenge-confirmed
food-allergic infants are scant. In one randomized, double-blind,
placebo-controlled study of infants with challenge-proven
CMA, administration of Lactobacillus casei CRL431 and
Bifidobacterium lactis Bb12 for 12 months did not affect the
acquisition of tolerance to cow’s milk (21). In contrast, we
demonstrated in two prospective clinical trials (22,23) that an
extensively hydrolyzed casein formula (EHCF) containing
Lactobacillus rhamnosus GG (LGG) accelerated the develop-
ment of tolerance acquisition in infants with CMA. When we
compared the fecal microbiota of infants receiving this tolerance-
inducing probiotic-supplemented therapy to that obtained
from infants receiving an EHCF alone, we found statistically
significant positive correlations between the abundance of genera
with the potential for producing butyrate and the concentration
of fecal butyrate in the infants that received EHCF supplemented
with LGG (11). Strain-level demarcations for butyrate producing
genera (including Roseburia, Coprococcus, and Blautia) ident-
ified in infants that acquired tolerance to cow’s milk suggest
that LGG treatment contributes to acquisition of tolerance by
altering the strain-level community structure of taxa with the
potential to produce butyrate (11). The mechanisms of action of
butyrate are multiple, but many of these involve an epigenetic
regulation of gene expression through the inhibition of histone
deacetylase (HDAC). The inhibition of HDAC 9 and 6 increases
FoxP3 gene expression, as well as the production and suppressive
function of Tregs (24). Our study group evaluated the
direct effects of butyrate on peripheral blood mononuclear cells
(PBMCs) from children affected by challenge-proven IgE-
mediated CMA. PBMCs were stimulated with BLG in the
presence or absence of butyrate. Preliminary results showed that
butyrate stimulates IL-10 and IFN-g production and decreases
DNA methylation rate of these two cytokines. Same effective
butyrate dose induces FoxP3 promoter region demethylation and
HDAC6/HDAC9 expression down-regulation.
CONCLUSIONS
The trillions of bacteria that populate our gut critically
regulate key physiological preventive functions against FA. Envir-
onmentally induced changes in the gut microbiota composition and
function (butyrate production) create dysbiosis that is linked to an
increased risk of FA occurrence. Understanding how gut bacteria
communities interact with the immune system are opening the way
to novel preventive and treatment strategies for FA.
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